You are here

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Tower
Seoul, , 04631 Korea, Republic of
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any patient who does not agree that Pfizer or companies working on behalf of Pfizer
can use his/her information.

- Patients with hypersensitivity to axitinib or to any other component of INLYTA® .

- Patients under 18.

- Pregnant women.

NCT02156895
Pfizer
Recruiting
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT02499120
All Genders
18+
Years
Multiple Sites
Metastatic Pancreatic Ductal Adenocarcinoma
NCT02501902
All Genders
18+
Years
Multiple Sites
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Inlyta
The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.
Investigators can choose any patient who is within the scope of I/E criteria
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Korea who has a disease for which Axitinib is indicated
Advanced Renal Cell Carcinoma
Drug: Axitinib
based on Axitinib approval
Patients who are using Axitinib
Intervention: Drug: Axitinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
3000
August 2018
August 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

Exclusion Criteria:

  • Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.
  • Patients with hypersensitivity to axitinib or to any other component of INLYTA® .
  • Patients under 18.
  • Pregnant women.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT02156895
A4061075
No
Not Provided
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now